Inclusion Criteria:

          -  Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) with documented evidence
             of progression during or after the participant's last treatment regimen based on the
             investigator's determination of the International Myeloma Working Group (IMWG)
             criteria.

               -  Relapsed defined as previously treated myeloma that progresses and requires
                  initiation of salvage therapy, but does not meet criteria for refractory myeloma.

               -  Refractory defined as disease that is nonresponsive (failure to achieve minimal
                  response or development of progressive disease) while on primary or salvage
                  therapy, or progresses within 60 days of last therapy.

          -  Measurable disease within 28 days prior to enrollment.

          -  Arm A - Lemzoparlimab (TJ011133) with or without Dexamethasone

               -  For Both Escalation and Expansion Phase, participant must have refractory to 3
                  prior lines of treatment including standard of care (SOC).

          -  Arm B - Lemzoparlimab (TJ011133) + Pomalidomide-Dexamethasone

               -  For Escalation Phase - Participant must have received at least 2 prior lines of
                  therapy, including lenalidomide and a Proteasome inhibitor (PI).

               -  For Expansion Phase - Participant must have received at least 1 prior line of
                  therapy, including lenalidomide and a Proteasome inhibitor (PI).

          -  Arm C - Lemzoparlimab (TJ011133) + Carfilzomib-Dexamethasone

               -  For Both Escalation and Expansion Phase - Participant must have received at least
                  1 prior line of therapy.

          -  Arm D - Lemzoparlimab (TJ011133) + Daratumumab-Dexamethasone

               -  For Escalation Phase: Participant must have received at least 3 prior lines of
                  therapy including a PI and an Immunomodulatory imide drug (IMiD).

               -  For Expansion Phase: Participant must have received at least 1 prior line of
                  therapy including a PI and an IMiD.

        Exclusion Criteria:

          -  Arm B - Lemzoparlimab (TJ011133) + Pomalidomide-Dexamethasone

               -  For Both Escalation and Expansion Phase participant must have had no prior
                  treatment with pomalidomide.

          -  Arm C - Lemzoparlimab (TJ011133) + Carfilzomib-Dexamethasone

               -  For Both Escalation and Expansion Phase - prior treatment with carfilzomib.

          -  Arm D - Lemzoparlimab (TJ011133) + Daratumumab-Dexamethasone

               -  For Both Escalation and Expansion Phase - prior treatment with daratumumab or
                  other anti-CD38 therapy.